IL86464A0 - Phosphorus-containing hmg-coa reductase inhibitor compounds and pharmaceutical compositions containing the same - Google Patents

Phosphorus-containing hmg-coa reductase inhibitor compounds and pharmaceutical compositions containing the same

Info

Publication number
IL86464A0
IL86464A0 IL86464A IL8646488A IL86464A0 IL 86464 A0 IL86464 A0 IL 86464A0 IL 86464 A IL86464 A IL 86464A IL 8646488 A IL8646488 A IL 8646488A IL 86464 A0 IL86464 A0 IL 86464A0
Authority
IL
Israel
Prior art keywords
phosphorus
pharmaceutical compositions
same
coa reductase
reductase inhibitor
Prior art date
Application number
IL86464A
Other versions
IL86464A (en
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Publication of IL86464A0 publication Critical patent/IL86464A0/en
Publication of IL86464A publication Critical patent/IL86464A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006Esters of acyclic acids which can have further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/30Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/30Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/301Acyclic saturated acids which can have further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/30Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/32Esters thereof
    • C07F9/3205Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/3211Esters of acyclic saturated acids which can have further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/30Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/36Amides thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808Acyclic saturated acids which can have further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44Amides thereof
    • C07F9/4403Amides thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4407Amides of acyclic saturated acids which can have further substituents on alkyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL86464A 1987-05-22 1988-05-20 4-phosphinyl-3- hydroxybutanoic acid derivatives useful as cholesterol biosynthesis inhibitors and pharmaceutical compositions containing the same IL86464A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5328187A 1987-05-22 1987-05-22
US10968087A 1987-10-19 1987-10-19

Publications (2)

Publication Number Publication Date
IL86464A0 true IL86464A0 (en) 1988-11-15
IL86464A IL86464A (en) 1993-06-10

Family

ID=26731667

Family Applications (1)

Application Number Title Priority Date Filing Date
IL86464A IL86464A (en) 1987-05-22 1988-05-20 4-phosphinyl-3- hydroxybutanoic acid derivatives useful as cholesterol biosynthesis inhibitors and pharmaceutical compositions containing the same

Country Status (24)

Country Link
JP (1) JP2680347B2 (en)
KR (1) KR880013958A (en)
CN (1) CN88103091A (en)
AU (1) AU610591B2 (en)
BE (1) BE1004193A3 (en)
CH (1) CH676984A5 (en)
DE (1) DE3817375C2 (en)
DK (1) DK277488A (en)
ES (1) ES2009918A6 (en)
FI (1) FI89493C (en)
FR (1) FR2615508B1 (en)
GB (1) GB2205837B (en)
GR (1) GR1000959B (en)
HU (1) HU205125B (en)
IE (2) IE63760B1 (en)
IL (1) IL86464A (en)
IT (1) IT1217685B (en)
NL (1) NL8801330A (en)
NO (1) NO882218L (en)
NZ (1) NZ224733A (en)
PH (1) PH25350A (en)
PL (1) PL154877B1 (en)
PT (1) PT87539B (en)
SE (1) SE503210C2 (en)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE501541C2 (en) * 1987-05-22 1995-03-06 Squibb & Sons Inc Phosphorus-containing HMG-CoA reductase inhibitors, novel intermediates and method
CA2007643A1 (en) * 1989-02-01 1990-08-01 Donald S. Karanewsky Combination of an hmg coa reductase inhibitor and a squalene synthetase inhibitor and method for lowering serum cholesterol using such combination
CA2042526A1 (en) * 1990-06-11 1991-12-12 Adeoye Y. Olukotun Method for preventing a second heart attack employing an hmg coa reductase inhibitor
US5202327A (en) * 1991-07-10 1993-04-13 E. R. Squibb & Sons, Inc. Phosphorus-containing hmg-coa reductase inhibitors
GB9126144D0 (en) * 1991-12-10 1992-02-12 British Bio Technology Compounds
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
WO2000015229A1 (en) 1998-09-17 2000-03-23 Bristol-Myers Squibb Company METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION
AU2002254567B2 (en) 2001-04-11 2007-10-11 Bristol-Myers Squibb Company Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
HUP0700151A2 (en) 2001-10-18 2007-05-29 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US6806381B2 (en) 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
ES2344057T3 (en) 2002-10-23 2010-08-17 Bristol-Myers Squibb Company INHIBITORS OF DIPEPTIDIL PEPTIDASA IV BASED ON GLICINE NITRILS.
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
US8158362B2 (en) 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
KR20060129082A (en) 2004-03-05 2006-12-14 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
US7145040B2 (en) 2004-07-02 2006-12-05 Bristol-Myers Squibb Co. Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
AR051446A1 (en) 2004-09-23 2007-01-17 Bristol Myers Squibb Co C-ARYL GLUCOSIDS AS SELECTIVE INHIBITORS OF GLUCOSE CONVEYORS (SGLT2)
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US7589088B2 (en) 2004-12-29 2009-09-15 Bristol-Myers Squibb Company Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7635699B2 (en) 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
WO2006076598A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7368458B2 (en) 2005-01-12 2008-05-06 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076568A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Thiazolopyridines as cannabinoid receptor modulators
WO2006078697A1 (en) 2005-01-18 2006-07-27 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
EP1879881A2 (en) 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
AR056155A1 (en) 2005-10-26 2007-09-19 Bristol Myers Squibb Co ANTAGONISTS OF NON-BASIC MELANINE CONCENTRATION HORMONE RECEIVER 1
WO2007053819A2 (en) 2005-10-31 2007-05-10 Bristol-Myers Squibb Company Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
US20100022457A1 (en) 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
WO2008057862A2 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
PE20090185A1 (en) 2007-03-22 2009-02-28 Bristol Myers Squibb Co PHARMACEUTICAL FORMULATIONS CONTAINING AN SGLT2 INHIBITOR
PE20090696A1 (en) 2007-04-20 2009-06-20 Bristol Myers Squibb Co CRYSTALLINE FORMS OF SAXAGLIPTIN AND PROCESSES FOR PREPARING THEM
JP5616220B2 (en) 2007-06-01 2014-10-29 ザ トラスティーズ オブ プリンストン ユニバーシティ Treatment of viral infections by regulating host cell metabolic pathways
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
JP2010534722A (en) 2007-07-27 2010-11-11 ブリストル−マイヤーズ スクイブ カンパニー Novel glucokinase activator and method of use thereof
CA2697551C (en) 2007-09-20 2013-03-12 Irm Llc Piperidine derivatives as modulators of gpr119 activity
PE20091928A1 (en) 2008-05-29 2009-12-31 Bristol Myers Squibb Co HAVE HYDROXYSUSTITUTED PYRIMIDINES AS NON-BASIC MELANIN-CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS
EA201101231A1 (en) 2009-03-27 2012-06-29 Бристол-Майерс Сквибб Компани METHODS TO PREVENT OR REDUCE THE RISK OF MORTALITY
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
CN102686579A (en) 2009-10-09 2012-09-19 Irm责任有限公司 Compounds and compositions as modulators of GPR119 activity
PT2498758T (en) 2009-11-13 2018-10-23 Astrazeneca Uk Ltd Bilayer tablet formulations
CA2780941C (en) 2009-11-13 2018-06-12 Bristol-Myers Squibb Company Immediate release tablet formulations
MX2012005425A (en) 2009-11-13 2012-06-14 Astrazeneca Uk Ltd Reduced mass metformin formulations.
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
US8592396B2 (en) 2010-04-14 2013-11-26 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
JP6042330B2 (en) 2010-07-09 2016-12-14 ビーエイチヴィ ファーマ、インコーポレイテッド Combined immediate / delayed delivery system for short half-life drugs including remogliflozin
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
TWI631963B (en) 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
CA2891773C (en) 2012-11-20 2021-01-19 Lexicon Pharmaceuticals, Inc. Inhibitors of sodium glucose cotransporter 1
WO2015027021A1 (en) 2013-08-22 2015-02-26 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
CN104610262B (en) * 2013-11-01 2017-06-06 上海医药工业研究院 Biphenyl compound, intermediate, preparation method, pharmaceutical composition and its application
MX2017013807A (en) 2015-04-30 2018-03-15 Harvard College Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders.
AU2019304032B2 (en) 2018-07-19 2021-12-09 Astrazeneca Ab Methods of treating HFpEF employing dapagliflozin and compositions comprising the same
BR112021004839A2 (en) 2018-09-26 2021-06-08 Lexicon Pharmaceuticals, Inc. crystalline forms of n-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2s,3r) ,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl)phenyl)butanamide and methods of its synthesis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA828650B (en) * 1981-12-01 1983-09-28 Hunt Chem Corp Philip A Herbicidal compositions and method using phosphonalkanoic acids, esters and salts thereof
FR2596393B1 (en) * 1986-04-01 1988-06-03 Sanofi Sa HYDROXY-3 DIHYDROXYOXOPHOSPHORIO-4 BUTANOIC ACID DERIVATIVES, THEIR PREPARATION PROCESS, THEIR USE AS MEDICAMENTS AND THE COMPOSITIONS CONTAINING THEM
SE501541C2 (en) * 1987-05-22 1995-03-06 Squibb & Sons Inc Phosphorus-containing HMG-CoA reductase inhibitors, novel intermediates and method

Also Published As

Publication number Publication date
GR1000959B (en) 1993-03-16
IT1217685B (en) 1990-03-30
GR880100331A (en) 1989-02-23
GB2205837A (en) 1988-12-21
HU205125B (en) 1992-03-30
PL272597A1 (en) 1989-03-06
FI882384A (en) 1988-11-23
HUT49358A (en) 1989-09-28
IE63760B1 (en) 1995-06-14
NO882218L (en) 1988-11-23
SE8801903D0 (en) 1988-05-20
NZ224733A (en) 1990-12-21
SE8801903L (en) 1988-11-23
FI89493B (en) 1993-06-30
BE1004193A3 (en) 1992-10-13
FI89493C (en) 1993-10-11
PT87539B (en) 1992-09-30
GB2205837B (en) 1991-11-20
NL8801330A (en) 1988-12-16
KR880013958A (en) 1988-12-22
PT87539A (en) 1989-05-31
JP2680347B2 (en) 1997-11-19
IE930324L (en) 1988-11-22
DK277488D0 (en) 1988-05-20
FI882384A0 (en) 1988-05-20
DE3817375C2 (en) 1997-04-30
PH25350A (en) 1991-05-13
PL154877B1 (en) 1991-09-30
CH676984A5 (en) 1991-03-28
AU610591B2 (en) 1991-05-23
FR2615508A1 (en) 1988-11-25
IL86464A (en) 1993-06-10
GB8811929D0 (en) 1988-06-22
JPS6456689A (en) 1989-03-03
DE3817375A1 (en) 1988-12-08
FR2615508B1 (en) 1994-11-25
IT8820682A0 (en) 1988-05-20
AU1650888A (en) 1988-11-24
NO882218D0 (en) 1988-05-20
IE881543L (en) 1988-11-22
ES2009918A6 (en) 1989-10-16
SE503210C2 (en) 1996-04-22
CN88103091A (en) 1988-12-21
DK277488A (en) 1988-11-23

Similar Documents

Publication Publication Date Title
IL86464A0 (en) Phosphorus-containing hmg-coa reductase inhibitor compounds and pharmaceutical compositions containing the same
JPS6426535A (en) Novel hmg-coa reductase inhibitor
IL79530A0 (en) Hmg-coa reductase inhibiting naphthalenol esters,their preparation and pharmaceutical compositions containing them
IL104041A0 (en) Stabilized pharmaceutical compositions comprising an hmg-coa reductase inhibitor compound
IL111785A0 (en) Dp-iv inhibitors and pharmaceutical compositions containing them
EP0251625A3 (en) Novel hmg-coa reductase inhibitors
IL105220A0 (en) Cyclohexanylidene compounds and pharmaceutical compositions containing them
HU9400952D0 (en) Heteroaryl-amines as acetyl-cholinesterase inhibitors
IL86463A0 (en) Phosphorus-containing hmg-coa reductase inhibitor compounds and pharmaceutical compositions containing the same
ZA925946B (en) Tetrahydroindazole tetrahydrocyclopentapyrazole and hexahydrocycloheptapyrazole compounds and their use as HMG-COA reductase inhibitors
EP0403487A4 (en) Novel hmg-coa reductase inhibitors
GR890100859A (en) Beta-aminoethyl substituted phenyl compounds and anti-inflammatory or analgesic compositions containing them
ZA886468B (en) Novel hmg-coa reductase inhibitors
EP0323866A3 (en) Novel hmg-coa reductase inhibitors
IL88502A0 (en) Pharmaceutical compositions containing an angiotensin converting enzyme inhibitor and methods for the preparation thereof
IL104418A0 (en) Disubstituted polycyclic compounds and pharmaceutical compositions containing them
EP0306263A3 (en) Novel hmg-coa reductase inhibitors
GB9303051D0 (en) 17b-nmonosubstituted carbamoyl-11-oxo-4-aza-5-a-androst-en-3-one testosterone-5-alpha reductase inhibitors
EP0468974A4 (en) Novel hmg-coa reductase inhibitors
ZA851426B (en) 17 beta-n-monosubstituted carbamoyl-4-aza-5 alpha-androst-1-en-3-ones as 5 alpha reductase inhibitors
ZA874487B (en) Novel hmg-coa reductase inhibitors
IE871654L (en) Novel hmg-coa reductase inhibitors
IE822652L (en) HMG-CoA REDUCTASE INHIBITORS
ZA894895B (en) 5-oxygenated hmg-coa reductase inhibitors
IE861739L (en) Hmg-coa reductase inhibitors

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees